RU1816283C - Process for preparing 4-aminopyridine derivatives - Google Patents

Process for preparing 4-aminopyridine derivatives

Info

Publication number
RU1816283C
RU1816283C SU884356604A SU4356604A RU1816283C RU 1816283 C RU1816283 C RU 1816283C SU 884356604 A SU884356604 A SU 884356604A SU 4356604 A SU4356604 A SU 4356604A RU 1816283 C RU1816283 C RU 1816283C
Authority
RU
Russia
Prior art keywords
ppm
amino
method described
reaction mixture
methylene chloride
Prior art date
Application number
SU884356604A
Other languages
Russian (ru)
Inventor
Чандрасинхджи Десай Манодж
Original Assignee
Пфайзер Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Пфайзер Инк. filed Critical Пфайзер Инк.
Application granted granted Critical
Publication of RU1816283C publication Critical patent/RU1816283C/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D219/00Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84Nitriles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00Carboxylic acid nitriles
    • C07C255/61Carboxylic acid nitriles containing cyano groups and nitrogen atoms being part of imino groups bound to the same carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84Nitriles
    • C07D213/85Nitriles in position 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D219/00Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
    • C07D219/04Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C07D219/08Nitrogen atoms
    • C07D219/10Nitrogen atoms attached in position 9
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D221/00Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04Ortho- or peri-condensed ring systems
    • C07D221/06Ring systems of three rings
    • C07D221/16Ring systems of three rings containing carbocyclic rings other than six-membered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D221/00Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22Bridged ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D309/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/68Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with nitrogen atoms directly attached in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30Hetero atoms other than halogen
    • C07D333/36Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D335/00Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/02Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D335/00Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/04Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D335/06Benzothiopyrans; Hydrogenated benzothiopyrans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Compounds of formula (I), wherein R<1>, R<2>, A and B are defined hereinbelow. The compounds of the present invention inhibit brain acetylcholinesterase and are useful in the treatment of Alzheimer's disease.

Description

Указанные свойства дают возможность предположить их использовани  в медицине .These properties make it possible to suggest their use in medicine.

Целью данного изобретени   вл етс  получение новых производных 4-аминопи- ридина, обладающих более высокой биологической активностью.An object of the present invention is to provide novel 4-aminopyridine derivatives having higher biological activity.

Эта цель заключаетс  в том, что соединение формулы IIThis objective is that the compound of formula II

CNCN

ооoo

где А и В имеют вышеуказанные значени , подвергают циклизации в присутствии основани .where A and B are as defined above, are cyclized in the presence of a base.

Пример. 9-Амино-1,2,3,4-тетрагид- ро-1,4-метаноакридин.Example. 9-amino-1,2,3,4-tetrahydro-1,4-methanoacridine.

Раствор антранилонитрила (3,6 г, 30,0 ммоль), норкам - фары (3,3 г, 30,0 ммоль) и п-толуолсульфоновой кислоты (50 мг) в бензоле (50 мл) нагревают при кип чении в приборе Дина-Старка. После нагревани  в течение 18 часов реакционную смесь охлаждают (25°С) и удал ют отделившуюс  воду (приблизительно 1,5 мл). Затем избыток бензола отгон ют в вакууме (1 мм рт. ст., 15 минут). Полученный таким образом масл нистый остаток раствор ют в тетрагидрофу- ране (ТГФ, 10 мл) и охлаждают до температуры 0°С, затем добавл ют раствор литийдиизопропиламида в ТГФ (1М, 36 мл, 36 ммоль). Потом эту реакционную смесь перемешивают при температуре 0°С в течение 3 часов. К концу этого периода времени реакцию прекращают путем добавлени  к реакционной смеси 40 мл воды и реакционную смесь экстрагируют метиленхлоридом (200 мл). Полученную органическую фазу промывают водой (2 х 50 мл) и сушат (безводный сульфат магни ). Метиленхлорид отгон ют в вакууме и получают остаток, который помещают в силикагельную колонку дл  флеш-хроматографии. Элюируют 5% метанола в метиленхлориде, содержащем 1 % триэтиламина, и получают целевой продукт в количестве 1.6 г (25%) в виде масла, твердеющего при сто нии. Т. пл. 185-186°С.A solution of anthranilonitrile (3.6 g, 30.0 mmol), mink headlights (3.3 g, 30.0 mmol) and p-toluenesulfonic acid (50 mg) in benzene (50 ml) are heated by boiling in a Dean device -Stark. After heating for 18 hours, the reaction mixture was cooled (25 ° C) and the separated water (approximately 1.5 ml) was removed. Then, excess benzene was distilled off in vacuo (1 mmHg, 15 minutes). The oily residue thus obtained was dissolved in tetrahydrofuran (THF, 10 ml) and cooled to 0 ° C, then a solution of lithium diisopropylamide in THF (1 M, 36 ml, 36 mmol) was added. Then this reaction mixture is stirred at a temperature of 0 ° C for 3 hours. At the end of this time, the reaction was stopped by adding 40 ml of water to the reaction mixture and the reaction mixture was extracted with methylene chloride (200 ml). The resulting organic phase was washed with water (2 x 50 ml) and dried (anhydrous magnesium sulfate). Methylene chloride was distilled off in vacuo to give a residue, which was placed on a flash chromatography silica gel column. 5% methanol in methylene chloride containing 1% triethylamine was eluted and the target product was obtained in an amount of 1.6 g (25%) as an oil that hardens upon standing. T. pl. 185-186 ° C.

Пример 2. 9-Амино-8-фтор-1,2.3,4- тетрагидро-1,4-метаноакридин.Example 2. 9-amino-8-fluoro-1,2.3,4-tetrahydro-1,4-methanoacridine.

По методике, описанной s примере 1, но с заменой антранилонитрила на 2-амино-6- фторбензонитрил получают целевой продукт . 23%, т. пл. 173°С.By the procedure described in Example 1, but with the replacement of anthranilonitrile with 2-amino-6-fluorobenzonitrile, the desired product is obtained. 23% mp 173 ° C.

ПримерЗ. 9-Амино-7-хлор-1,2,3,4-тет- рагидро-1,4-метаноакридин.Example 3. 9-amino-7-chloro-1,2,3,4-tetrahydro-1,4-methanoacridine.

По методике, описанной в примере 1, но с заменой антранилонитрила на 2-амино-5хлорбензонитрил получают целевой продукт , 14%, т. пл. 183-184°С.By the method described in example 1, but with the replacement of anthranilonitrile with 2-amino-5-chlorobenzonitrile, the desired product is obtained, 14%, mp 183-184 ° C.

П р и м е р 4. 9-Амино-1,4-дигидро-1,4- метаноакридинPRI me R 4. 9-amino-1,4-dihydro-1,4-methanoacridine

По методике, описанной в примере 1, но с заменой норкам-фары на 5-норборнен-2- он получают целевой продукт 26%. т. пл. 123°С.By the methodology described in example 1, but with the replacement of mink headlights with 5-norbornene-2- he received the target product 26%. t. pl. 123 ° C.

Пример 5.9-Амино-2-окса-1,2,3,4-тетрагидроакридин .Example 5.9-Amino-2-oxa-1,2,3,4-tetrahydroacridine.

Антранилонитрил (2,95 г, 25 ммоль), хлорид цинка (3,1 г, 25 ммоль) и тетрагидро-4Н- пиран-4-он раствор ют в толуоле (40 мл) и нагревают с рефлюксом в течение 2,5 дн . КAnthranilonitrile (2.95 g, 25 mmol), zinc chloride (3.1 g, 25 mmol) and tetrahydro-4H-pyran-4-one were dissolved in toluene (40 ml) and heated with reflux for 2.5 days . TO

5 концу этого периода реакционную смесь охлаждают (25°С), разбавл ют водным раствором гидроксида натри  (70 мл) и экстрагируют метиленхлоридом (4 х 60 мл). Соединенные органические фазы промыва0 ют водой (2 х 100 мл) и высушивают (безвод- ный сульфат магни ). Органические растворители удал ют в вакууме и получают желтый остаток, который загружают в силикагельную колонку дл  флеш-хроматогрэ5 фии. Элюируют 5% метанола в метиленхлориде и получают целевой продукт в виде желтых кристаллов, 155 мг, 31 %, т. пл. 195-196°С.At the end of this period, the reaction mixture was cooled (25 ° C), diluted with an aqueous solution of sodium hydroxide (70 ml) and extracted with methylene chloride (4 x 60 ml). The combined organic phases are washed with water (2 x 100 ml) and dried (anhydrous magnesium sulfate). The organic solvents were removed in vacuo to give a yellow residue, which was loaded onto a silica gel flash chromatography column. Elute 5% methanol in methylene chloride to obtain the desired product in the form of yellow crystals, 155 mg, 31%, mp 195-196 ° C.

Пример 6. 9-Амино-2-тиа-1,2,3,4-тет0 рагидроакридин.Example 6. 9-amino-2-thia-1,2,3,4-tet0 rahydroacridine.

Антранилонитрил (2,6 г, 21,5 ммоль), тетрагидротиопиран-4-он (5,0 г, 43 ммоль) и хлорид цинка (2,54 г, 21,5 ммоль) соедин ют и нагревают до температуры 120°С в тече5 ние 20 минут. Реакционную смесь охлаждают в твердый остаток, отфильтровывают с применением этилового эфира (100 мл). Полученное твердое вещество оранжевого цвета (5,2 г) помещают в химический стакан,Anthranilonitrile (2.6 g, 21.5 mmol), tetrahydrothiopyran-4-one (5.0 g, 43 mmol) and zinc chloride (2.54 g, 21.5 mmol) are combined and heated to a temperature of 120 ° C. for 20 minutes. The reaction mixture was cooled to a solid residue, filtered using ethyl ether (100 ml). The obtained orange solid (5.2 g) was placed in a beaker,

0 содержащий насыщенный раствор ЭДТК (этилендиаминтетрауксусна  кислота) в воде (125 мл) и рН довод т до 13 при помощи 12% водного раствора гидроксида натри . Затем водную фазу экстрагируют метиленх5 лоридом (4 х 50 мл) и экстракт промывают водой (2 х 70 мл) и высушивают (сульфат магни ). После удалени  метиленхлорида в вакууме получают желтую пасту (2,0 г), которую растирают с эфиром и фильтруют, пол0 учают твердое вещество светло-желтого цвета, 1,36 г, 29%, т. пл. 205°С (разлагаетс ). Пример. 9-Амино-4-окса-1,2,3,4-тет- рагидроакридин.0 containing a saturated solution of EDTA (ethylenediaminetetraacetic acid) in water (125 ml) and the pH was adjusted to 13 with a 12% aqueous sodium hydroxide solution. The aqueous phase is then extracted with methylenex5 loride (4 x 50 ml) and the extract is washed with water (2 x 70 ml) and dried (magnesium sulfate). After removal of methylene chloride in vacuo, a yellow paste (2.0 g) is obtained, which is triturated with ether and filtered, a pale yellow solid, 1.36 g, 29%, mp. 205 ° C (decomposes). Example. 9-amino-4-oxa-1,2,3,4-tetrahydroacridine.

К перемешиваемому при температуреTo mix at temperature

5 -20°С раствору дельта-%валеролактона (1,0 г. 10,0 ммоль) в метиленхлориде (10 мл) добавл ют 1 М раствор хлорида титана (IV) в метиленхлориде(20 мл). Реакционна  смесь приобретает темно-желтую окраску, и к ней добавл ют смесь триэтиламина (2,0 г, 20A solution of delta% valerolactone (1.0 g, 10.0 mmol) in methylene chloride (10 ml) was added with a 1 M solution of titanium (IV) chloride in methylene chloride (20 ml). The reaction mixture turned a dark yellow color, and a mixture of triethylamine (2.0 g, 20

ммоль) и знтранилонитрила (1,2 г, 10,0 ммоль) в метиленхлориде (30 мл). Реакционна  смесь сразу же становитс  темной, ее оставл ют нагреватьс  до комнатной температуры (приблизительно 25°С) и затем перемешивают в течение 15 часов. К концу этого периода реакционную смесь обрабатывают 25% водным раствором гидроксида натри  (40 мл) и метиленхлоридом (100 мл) и фильтруют через прокладку из диатомовой земли толщиной 2 дюйма (торговое название целит, Ceflt), которую промывают метиленхлоридом (50 мл) и водой (100 мл). Органический слой отдел ют, промывают один раз водой (30 мл) и высушивают (безводный сульфат магни ). Метиленхлорид отгон ют в вакууме и получают масло, которое растирают с эфиром, получают целевой продукт в виде белого твердого вещества, 565 мг, 28%.mmol) and zntranilonitrile (1.2 g, 10.0 mmol) in methylene chloride (30 ml). The reaction mixture immediately darkens, it is allowed to warm to room temperature (approximately 25 ° C) and then stirred for 15 hours. At the end of this period, the reaction mixture was treated with a 25% aqueous solution of sodium hydroxide (40 ml) and methylene chloride (100 ml) and filtered through a 2 inch thick pad of diatomaceous earth (trade name Celite, Ceflt), which was washed with methylene chloride (50 ml) and water (100 ml). The organic layer was separated, washed once with water (30 ml) and dried (anhydrous magnesium sulfate). Methylene chloride was distilled off in vacuo to give an oil which was triturated with ether to give the desired product as a white solid, 565 mg, 28%.

IH-ЯМР (CDCI3. 300 МГц, д ); 2Н, т, 2,02-2,18м.д„-2H,t,2,63 м.д.(J 6.0Гц);2Н, t, 4,36 М.д. 0 6,0 Гц); 2Н, S, 4,64 м.д.; IH, t, 7,25 (f 9,0 Гц), IH. t, 7,5Q 8,0 Гц); IH, d, 7,72 (I - 8,0 Гц).1 H NMR (CDCI 3. 300 MHz, d); 2H, t, 2.02-2.18 ppm „-2H, t, 2.63 ppm (J 6.0Hz); 2H, t, 4.36 ppm. 0 6.0 Hz); 2H, S, 4.64 ppm; IH, t, 7.25 (f 9.0 Hz), IH. t, 7.5Q 8.0 Hz); IH, d, 7.72 (I - 8.0 Hz).

Примере. 9-Амино-8-фтор-4-окса- 1,2,3,4-тетрагидроакридин.An example. 9-amino-8-fluoro-4-oxa-1,2,3,4-tetrahydroacridine.

По методике, описанной в примере 7. но с заменой антранилонитрила на 2-амино-6- фторбензонитрил получают целевой продукт , 8%, т.пл. 195-196°С.By the method described in example 7. but with the replacement of anthranilonitrile with 2-amino-6-fluorobenzonitrile, the desired product is obtained, 8%, mp. 195-196 ° C.

П р и м е р 9. 9-Амино-7-хлор-4-окса- 1,2,3,4-тетрагидроакридин.PRI me R 9. 9-amino-7-chloro-4-oxa-1,2,3,4-tetrahydroacridine.

По методике, описанной в примере 7, но с заменой антранилонитрила на 2-амино-5- хлорбензонитрил получают целевой продукт , 2%, т.пл. 2 78-279°С.By the method described in example 7, but with the replacement of anthranilonitrile with 2-amino-5-chlorobenzonitrile, the desired product is obtained, 2%, mp. 2 78-279 ° C.

Пример 10. 9-Амино-4-окса- 1,2,3,4,5,6,7,8-октагидроакридин.Example 10. 9-amino-4-oxa-1,2,3,4,5,6,7,8-octahydroacridine.

По методу, описанному в примере 7, но с заменой антранилонитрила на 2-амино-1- циано-1-циклогексен получают целевой продукт, 8%, т.пл. 145°С.By the method described in example 7, but with the replacement of anthranilonitrile with 2-amino-1-cyano-1-cyclohexene, the target product is obtained, 8%, mp. 145 ° C.

П р и м е р 11.9-Амино-2,3,7,8-тетрагид- ро-1Н-циклопента(е)-6Н-пирано(-)2, З -в) пиридин.Example 11.9-Amino-2,3,7,8-tetrahydro-1H-cyclopenta (e) -6H-pyrano (-) 2, 3-c) pyridine.

По методу, описанному в примере 7, но с заменой антранилонитрила на 2-амино-1- циано-1-циклопентен получают целевой продукт, 22%, т.пл, 164°С.According to the method described in example 7, but with the replacement of anthranilonitrile with 2-amino-1-cyano-1-cyclopentene, the desired product is obtained, 22%, mp 164 ° C.

Пример 12. 2,3-Дигидротиено(3,2- в)хинолин-9-амин.Example 12. 2,3-Dihydrothieno (3,2-c) quinolin-9-amine.

К перемешиваемому при температуре -78°С раствору тетрагидротиофен-3-она (1,1 г, 11 моль) в метиленхлориде (10 мл) добавл ют 1 М раствор хлорида титана (IV) в метиленхлориде (11 мл). Затем к реакционной смеси добавл ют в течение 5 минут смесь триэтиламина (2,2 г. 22 ммоль) и антранилонитрила (1,2 г, 10,0 ммоль) в метиленхлориде (30 мл) После этого реакционную смесь медленно нагревают до комнатной температуры и перемешивают в течение 2 часов. Потом добавл ют к реакционной смеси тет5 рагидротиофен-3-он (1 мл) и хлорид титана (IV) (1,0 мл) и смесь перемешивают при температуре 25°С в течение 16 часов. Затем к реакционной смеси быстро приливают 12% водный раствор гидроксида натри  (100 мл),To a solution of tetrahydrothiophen-3-one (1.1 g, 11 mol) in methylene chloride (10 ml) stirred at -78 ° C was added a 1 M solution of titanium (IV) chloride in methylene chloride (11 ml). Then, a mixture of triethylamine (2.2 g, 22 mmol) and anthranilonitrile (1.2 g, 10.0 mmol) in methylene chloride (30 ml) was added to the reaction mixture over 5 minutes, after which the reaction mixture was slowly warmed to room temperature and stirred for 2 hours. Then, rahydrothiophen-3-one (1 ml) and titanium (IV) chloride (1.0 ml) were added to the tet5 reaction mixture, and the mixture was stirred at 25 ° C for 16 hours. Then a 12% aqueous solution of sodium hydroxide (100 ml) was quickly added to the reaction mixture,

0 после чего реакционную смесь энергично перемешивают с дополнительным количеством метиленхлорида (300 мл). Затем реакционную смесь фильтруют через диатомовую землк.(торговое название целит) и органи5 ческую фазу отдел ют. Органические растворители удал ют в вакууме и получают остаток, который загружают в флеш-хрома- тографическую колонку. Элюируют 5% метанола в метиленхлориде, содержащем 1 %0 after which the reaction mixture was vigorously stirred with an additional amount of methylene chloride (300 ml). The reaction mixture was then filtered through a diatomaceous earth (trade name Celite) and the organic phase was separated. The organic solvents were removed in vacuo to give a residue, which was loaded onto a flash chromatography column. Elute 5% methanol in methylene chloride containing 1%

0 триэтиламина, и получают целевой продукт. (13 г, 64%), которое кристаллизуют из хлороформа , 560 мг, 32%. т.пл. 208-210°С.0 triethylamine, and get the target product. (13 g, 64%), which crystallizes from chloroform, 560 mg, 32%. so pl. 208-210 ° C.

П р и м е р 13.9-Амино-1,2,3,4.5,6,7,8-ок- тагидро-1,4-метаноакридин.Example 13.9-amino-1,2,3,4.5,6,7,8-octahydro-1,4-methanoacridine

5 К перемешиваемому при температуре -20°С раствору норкамфоры (0,9 г, 8.2 ммоль) в метиленхлориде (8,0 мл) добавл ют смесь триэтиламина (1,7 г, 16,4 ммоль) и 2-амино-1-циано-1-циклогексена (1,0 г, 8,25 A mixture of triethylamine (1.7 g, 16.4 mmol) and 2-amino-1- was added to a solution of norkormora (0.9 g, 8.2 mmol) in methylene chloride (8.0 ml) stirred at -20 ° C. cyano-1-cyclohexene (1.0 g, 8.2

0 ммоль) в метиленхлориде (24 мл) и полученную смесь перемешивают при температуре 25°С в течение 15 минут. Затем к реакционной смеси быстро приливают 12% водный раствор гидроксида натри  (60 мл) и энер5 гично перемешивают с метиленхлоридом (60 мл). После этого реакционную смесь фильтруют через прокладку из диатомовой земли толщиной 2 дюйма (торговое название целит). Органическую фазу отдел ют,0 mmol) in methylene chloride (24 ml) and the resulting mixture was stirred at 25 ° C for 15 minutes. Then a 12% aqueous solution of sodium hydroxide (60 ml) was quickly poured into the reaction mixture and vigorously stirred with methylene chloride (60 ml). After that, the reaction mixture is filtered through a 2-inch-thick diatomaceous earth pad (trade name Celite). The organic phase is separated

0 промывают, водой (2 х 50 мл) и затем сушат (безводный сульфат магни ). Потом мети- лёнхлорид удал ют при пониженном давлении и получают масло, которое растирают с пентаном, получают целевой продукт в виде0 was washed with water (2 x 50 ml) and then dried (anhydrous magnesium sulfate). Then, methylene chloride is removed under reduced pressure to give an oil, which is triturated with pentane to give the desired product in the form

5 беловатого твердого вещества, 225 мг, 13%, т.пл. 131-133°С.5 whitish solid, 225 mg, 13%, mp. 131-133 ° C.

П р и м е р 14.9-Амино-6-аза-1,2,3,4-тетрагидроакридин .PRI me R 14.9-amino-6-aza-1,2,3,4-tetrahydroacridine.

Хлорид титана (IV) (1,5 мл) добавл ют кTitanium (IV) chloride (1.5 ml) is added to

0 перемешиваемому раствору З-амино-4-циа- нопиридина (500 мг, 4,2 ммоль) и циклогек- санона (0,05 мл) в 1,2-дихлорэтане (15 мл). Затем реакционную смесь выдерживают при температуре 90°С в течение 12 часов. КTo a stirred solution of 3-amino-4-cyanopyridine (500 mg, 4.2 mmol) and cyclohexanone (0.05 ml) in 1,2-dichloroethane (15 ml). Then the reaction mixture was kept at a temperature of 90 ° C for 12 hours. TO

5 концу этого периода к реакционной смеси добавл ют циклогексанон (2,0 мл) и 1,2-дих- лорэтан (5.0 мл) и нагревание продолжают в течение еще 12 часов. Затем добавл ют дополнительные количества циклогексанона (2,0 мл) и хлорида титана (IV) (1,2 мл) и pea кционную смесь выдерживают при температуре 90°С в течение б ч. Затем реакционную смесь охлаждают и быстро приливают к ней 5% водный раствор гидроксида натри  (25 мл) и энергично перемешивают с метиленх- лоридом (200 мл, 25 мин). Потом реакционную смесь обрабатывают, как описано в примере 8, и получают целевой продукт (170 мг, 95%-на  чистота, 20%) после флеш-хро- матографии на силикагеле (элюент 95:5:1 метиленхлорид:метанол-гидроксид аммони ). Этот материал дополнительно очищают методом хроматографии и получают целевой продукт, 75 мг, т.пл. 180-181°С.At the end of this period, cyclohexanone (2.0 ml) and 1,2-dichloroethane (5.0 ml) were added to the reaction mixture, and heating was continued for another 12 hours. Then additional quantities of cyclohexanone (2.0 ml) and titanium (IV) chloride (1.2 ml) were added and the reaction mixture was kept at 90 ° C for b hours. Then the reaction mixture was cooled and 5% was quickly added to it. aqueous sodium hydroxide solution (25 ml) and vigorously stirred with methylene chloride (200 ml, 25 min). Then the reaction mixture is treated as described in example 8, and the desired product (170 mg, 95% pure, 20%) is obtained after flash chromatography on silica gel (eluent 95: 5: 1 methylene chloride: methanol-ammonium hydroxide) . This material is further purified by chromatography and get the target product, 75 mg, so pl. 180-181 ° C.

П р и м е р 15.9-Амино-5-аза-1,2,3,4-тет- рагидроакридинPRI me R 15.9-Amino-5-aza-1,2,3,4-tetrahydroacridine

По методу, описанному в примере 12, но с заменой З-амйно-4-цианопиридина на 2- амино-3-цианопиридин получают целевой продукт, 38%, т. пл. 225-228°С (разлагаетс ).By the method described in example 12, but with the replacement of 3-amino-4-cyanopyridine with 2-amino-3-cyanopyridine, the desired product is obtained, 38%, mp. 225-228 ° C (decomposes).

Ш-ЯРМ (CDCI3 + CD3OD, 300 МГц, д ) :4Н, bS, 1,8бм.д.;W-NMR (CDCI3 + CD3OD, 300 MHz, d): 4H, bS, 1.8 bpm;

2Н, Bt, 2,5 м.д.; 2Н, Bt, 2,97 м.д.; 2Н, veS, 3,0-3,3 м.д.;2H, Bt, 2.5 ppm; 2H, Bt, 2.97 ppm; 2H, veS, 3.0-3.3 ppm;

IH, dd, 7,2 м.д. 0 8,04,0 Гц); IH, dd, 8,18 м.д.IH, dd, 7.2 ppm. 0 8.04.0 Hz); IH, dd, 8.18 ppm.

О 8.0. 1-2 Гц); IH, dd, 8,77 м.д. О - 4,0, 1-2 Гц).About 8.0. 1-2 Hz); IH, dd, 8.77 ppm. O - 4.0, 1-2 Hz).

Пример 16. 9-Амино-4,5-оксаза- 1,2,3,4-тетрагидроакридинExample 16. 9-amino-4,5-oxase-1,2,3,4-tetrahydroacridine

К перемешиваемому раствору 2-амино- 3-цианопиридина (360 мг, 3,0 ммоль) и дель- та-валеролактора (360 мг, 3,6 ммоль) в 1,2-дихлорэтане (7,0 мл) добавл ют хлорид титана (IV) (0,9 мл), после чего реакционную смесь выдерживают при температуре 90°С в течение 18 ч. После этого реакционную смесь быстро охлаждают путем добавлени  15% водного раствора гидроксида натри  (200 мл) и энергично перемешивают с мети- ленхлоридом (200 мл, 25 мин). Потом реакционную смесь обрабатывают так, как описано в примере 15, и получают целевой продукт, 8%, т.пл. 269-270°С (разлагаетс ).To a stirred solution of 2-amino-3-cyanopyridine (360 mg, 3.0 mmol) and delta-valerolactor (360 mg, 3.6 mmol) in 1,2-dichloroethane (7.0 ml), titanium chloride (IV) (0.9 ml), after which the reaction mixture was kept at a temperature of 90 ° C for 18 hours. After that, the reaction mixture was quickly cooled by adding 15% aqueous sodium hydroxide solution (200 ml) and stirred vigorously with methylene chloride (200 ml, 25 min). Then the reaction mixture is treated as described in example 15, and get the target product, 8%, so pl. 269-270 ° C (decomposes).

П«р и м е р 17. 9-Амино-4,6-оксаза- 1,2,3,4-тетрагидроакридинPRI me R 17. 9-amino-4,6-oxase-1,2,3,4-tetrahydroacridine

По методу, описанному в примере 16, но с применением З-амино-4-цианопиридина вместо 2-амино-З-цианопиридинз получают целевой продукт, 16%, т.пл. 237-238°С.According to the method described in example 16, but using 3-amino-4-cyanopyridine instead of 2-amino-3-cyanopyridines, the target product is obtained, 16%, mp. 237-238 ° C.

П р и м е р 18.9-Амино-5-аза-1,2,3,4-тет- рагидро-1,4-метаноакридинPRI me R 18.9-Amino-5-aza-1,2,3,4-tetrahydro-1,4-methanoacridine

По методу, описанному в примере 16, но с применением норкамфоры вместо дельта- валеролактона получают целевой продукт, (29%. т.пл. 243-244°С).By the method described in example 16, but using norkormora instead of delta-valerolactone, the desired product is obtained (29%, mp 243-244 ° C).

Пример 9.9-Амино-6-аза-1,2,3,4-тет- рагидро-1,4-метаноакридинExample 9.9-Amino-6-aza-1,2,3,4-tetrahydro-1,4-methanoacridine

По методу, описанному в примере 16. ноAccording to the method described in example 16. but

с применением норкамфоры вместо дельтавалеролактона и З-амино-4-цианопиридинаusing norkamfora instead of deltavalerolactone and 3-amino-4-cyanopyridine

вместо 2-амино-З-цианопиридина получаютinstead of 2-amino-3-cyanopyridine get

целевой продукт (16%, т.пл. 236-237°С).target product (16%, mp 236-237 ° C).

П р и м е р 20, 9-Циклогексилметилами- но-8-фтор-4-окса-1,2,3,4-тетрэгидроакрид- инPRI me R 20, 9-Cyclohexylmethylamino-8-fluoro-4-oxa-1,2,3,4-tetrahydroacridine

Смесь гидрида натри  (60% масло, 110 0 мг, 2,75 ммоль), указанного в заголовке примера 6 соединени  (600 мг, 2,75 ммоль) цик- логексилметилбромида (487 мг, 2,75 ммоль) и диметилформамида (3,0 мл) нагревают при перемешивании при температуре 25°С в те- 5 чение 12 часов, затем при температуре 65°С в течение 12 часов. К концу этого периода реакционную смесь быстро охлаждают, выливают ее в воду (45 мл) и затем полученную смесь экстрагируют эилацетатом (3 х 40 мл) 0 и высушивают (безводный сульфат магни ). Этилацетат отгон ют в вакууме и получают остаток, который загружают в колонку с си- ликагелем, предназначенную дл  флеш-хро- матографии. Элюируют этил-ацетатом и 5 получают масло, твердеющее при сто нии. При растирании этого твердого вещества с пентаном получают целевой продукт (110 мг, 13%) в виде желтовато-коричневого кристаллического вещества, т.пл. 100°С. 0 Пример21.9-Циклогексилэтиламино- 8-фтор-4-окса-1,2,3,4-тетрагидроакридинA mixture of sodium hydride (60% oil, 110 0 mg, 2.75 mmol), the title of Example 6 of the compound (600 mg, 2.75 mmol) of cyclohexylmethyl bromide (487 mg, 2.75 mmol) and dimethylformamide (3, 0 ml) is heated with stirring at a temperature of 25 ° C for 5 hours, then at a temperature of 65 ° C for 12 hours. At the end of this period, the reaction mixture was rapidly cooled, poured into water (45 ml) and then the resulting mixture was extracted with ethyl acetate (3 x 40 ml) 0 and dried (anhydrous magnesium sulfate). Ethyl acetate was distilled off in vacuo to give a residue, which was loaded onto a silica gel column for flash chromatography. Elute with ethyl acetate and 5 give an oil that solidifies on standing. Trituration of this solid with pentane gave the desired product (110 mg, 13%) as a tan crystalline solid, mp. 100 ° C. 0 Example 21.9-Cyclohexylethylamino-8-fluoro-4-oxa-1,2,3,4-tetrahydroacridine

По методу, описанному в примере 20, но с применением циклогексилэтилбромида вместо циклогексилметилбромида получа- 5 ют целевой продукт (34%).By the method described in Example 20, but using cyclohexyl ethyl bromide instead of cyclohexyl methyl bromide, the desired product is obtained (34%).

IH-ЯРМ (CD , 300 МГц, д ): 2Н, т, 0,8-1,02 м.д.;4Н, т,IH-NMR (CD, 300 MHz, d): 2H, t, 0.8-1.02 ppm; 4H, t,

1,02-1,4 м.д.; 2Н, т, 1,44-1,56 м.д.; 5Н, Bd, 1,56-1,8 м.д.; 2Н, а, 1,92-2,04 м. д. О 0 6,0 Гц); 2Н, t, 2,8 м.д. 0 6 Гц); 2Н, в:, 3,33 м.д.; 2Н, t, 4,36 м.д. О 6 Гц); IH, Bd- 5,6 м.д. (1 20Гц); IH, dd, 6,38 м. д. О 14,0, 7,5 Гц); IH, dd, 7,24-7,38 м.д.; IH.d, 7,48 м.д. 0 8,2 Гц). 5 П р и м е р 22. 9-Бензиламино-8-фтор-4- окса-1,2,3,4-тетрагидроакридин1.02-1.4 ppm; 2H, t, 1.44-1.56 ppm; 5H, Bd, 1.56-1.8 ppm; 2H, a, 1.92-2.04 ppm, O 0 6.0 Hz); 2H, t, 2.8 ppm. 0 6 Hz); 2H, in :, 3.33 ppm; 2H, t, 4.36 ppm. About 6 Hz); IH, Bd - 5.6 ppm. (1 20Hz); IH, dd, 6.38 ppm, O 14.0, 7.5 Hz); IH, dd, 7.24-7.38 ppm; IH.d, 7.48 ppm. 0 8.2 Hz). 5 PRI me R 22. 9-Benzylamino-8-fluoro-4-oxa-1,2,3,4-tetrahydroacridine

По методу, описанному в примере 20, но с заменой циклогексилметилбромида на бензилбромид получают целевой продукт, 0 38%, т.пл. 134-135°С.By the method described in example 20, but with the replacement of cyclohexylmethyl bromide with benzyl bromide, the desired product is obtained, 0 38%, mp 134-135 ° C.

П р и м е р 23. 9-Фенетиламийо-8-фтор- 4-окса-1,2,3,4-тетрагидрозкридинPRI me R 23. 9-Phenetilamiyo-8-fluoro-4-oxa-1,2,3,4-tetrahydrozcridine

По методу, описанному в примере 20, но с заменой циклогексилметилбромида на (2- 5 бромэтил) бензол получают целевой продукт . 20%, т.пл. 225-126°С.By the method described in example 20, but with the replacement of cyclohexylmethyl bromide with (2-5 bromoethyl) benzene, the desired product is obtained. 20% mp 225-126 ° C.

П р и м е р 24. 9-Фенпропиламино-8- фтор-4-окса-1,2,3,4-тетрагидроакридинPRI me R 24. 9-Phenpropylamino-8-fluoro-4-oxa-1,2,3,4-tetrahydroacridine

По методу, описанному в примере 20, но с заменой циклогексилметилбромида на 1бром-3-ффенилпропан получают целевой продукт (53% масло).By the method described in example 20, but with the replacement of cyclohexylmethyl bromide with 1 bromo-3-phenylpropane, the desired product is obtained (53% oil).

IH-ЯМР (CDCI.3, 300 МГц, б ): 4Н, т, 1.82-2,02 м.д.;4Н, т,IH-NMR (CDCI.3, 300 MHz, b): 4H, t, 1.82-2.02 ppm; 4H, t,

2.62-2,78 м.д.; 2Н, в5, 2,34 м.д.; 2Н, t, 4,35 м.д.2.62-2.78 ppm; 2H, b5, 2.34 ppm; 2H, t, 4.35 ppm.

О - 6,0 Гц); IH, вО. 5,7 м.д. О - 20 Гц); IH, dd,O - 6.0 Hz); IH, VO. 5.7 ppm O - 20 Hz); IH, dd,

6.86 м.д. (I - 14, 7,5 Гц); 6Н, т, 7.04-7,4 м.д.; IH, d,6.86 ppm (I - 14, 7.5 Hz); 6H, t, 7.04-7.4 ppm; IH, d

7.51 м.д. (|-8,2 Гц).7.51 ppm (| -8.2 Hz).

П р и м е р 25. 9-(3,3-Дифенилпропила- мино)-8-фтор-4-окса-1,2,3,4- тетрагидроак- ридинPRI me R 25. 9- (3,3-Diphenylpropylamino) -8-fluoro-4-oxa-1,2,3,4-tetrahydroacridine

По методу, описанному в примере 20, но с заменой циклогексилметилбромида на 1- . бром-3,3-дифенилпропан получают целевой продукт, 32%,т.пл. 134-135°С.According to the method described in example 20, but with the replacement of cyclohexylmethyl bromide by 1-. bromo-3,3-diphenylpropane get the target product, 32%, so pl. 134-135 ° C.

П р и м е р 26. 9-Амино-4-тиа-1,2, 3,4-тет- рагидроакридинPRI me R 26. 9-amino-4-thia-1,2, 3,4-tetrahydroacridine

По методу, описанному в примере 7, но с заменой дельтавалеролактона на дельта- тиовалеролактон получают целевой продукт 4%,т.пл. 190°С.According to the method described in example 7, but with the replacement of deltavalerolactone by deltovovalerolactone, the desired product is obtained 4%, mp. 190 ° C.

П р и м е р 27. 9-Амино-3-метил-4-окса- 1,2,3,4-тетрагидроакридинPRI me R 27. 9-amino-3-methyl-4-oxa-1,2,3,4-tetrahydroacridine

По методу, описанному в примере 7, но с заменой дельтавалеролактона на 6-метил- тетрагидропиран-2-он получают целевой продукт, 23%, т.пл. 202-203°С.By the method described in example 7, but with the replacement of deltavalerolactone with 6-methyl-tetrahydropyran-2-one, the desired product is obtained, 23%, mp. 202-203 ° C.

П р и м е р 28. 9-Амино-3-метил-8-фтор- 4-окса-1,2,3,4-тетрагидроакридинPRI me R 28. 9-amino-3-methyl-8-fluoro-4-oxa-1,2,3,4-tetrahydroacridine

По способу, описанному в примере 7, но с заменой дельта-валеролактона на 6-ме- тилтетрагидропиран-2-он и антранило-нит- рила на 2-амино-6-фторбензонитрил получают указанное в заголовке соединение , 13%, т.пл. 217-218°С.By the method described in example 7, but with the replacement of delta-valerolactone with 6-methyltetrahydropyran-2-one and anthranilo-nitrile with 2-amino-6-fluorobenzonitrile, the title compound was obtained, 13%, mp . 217-218 ° C.

П р и м е р 29. 9-Амино-8-фтор-2-тиа- 1,2,3,4-тетрагидроакридинPRI me R 29. 9-amino-8-fluoro-2-thia-1,2,3,4-tetrahydroacridine

По способу, описанному в примере 7, но с заменой дельта-валеролактона на тетра- нитротиопиран-4-он и антранилрнитрала на 2-амино-б-фторбензонитрил получают це-. левой продукт 19%, т.пл. 175-17б°С.According to the method described in Example 7, but with the replacement of delta-valerolactone with tetranitrothiopyran-4-one and anthranyl nitranyl with 2-amino-b-fluorobenzonitrile, ce is obtained. left product 19% mp 175-17b ° C.

П р и м е р 30. 9-Амино-1,2,3,4-тетрагид- ро-1,4-этаноакридинPRI me R 30. 9-amino-1,2,3,4-tetrahydro-1,4-ethanoacridine

По способу, описанному в примере 1, но с применением дицикло (2,2.2) октан-2-она вместо норкамфоры получают целевой продукт , 20%, т.пл. 197-199°С.By the method described in example 1, but using dicyclo (2.2.2) octan-2-one, instead of minkfort, the target product is obtained, 20%, mp 197-199 ° C.

П р и м е р 31. 2,3-Дигидрофуро(2,3-в)хи- нолин-4-аминPRI me R 31. 2,3-Dihydrofuro (2,3-b) quinolin-4-amine

По способу, описанному в примере 7, но с применением гаммабутиролактона вместо дельта-валеролактона получают целевой продукт, т.пл. 300°С (разлагаетс ).By the method described in example 7, but using gamma-butyrolactone instead of delta-valerolactone, the desired product is obtained, mp 300 ° C (decomposes).

IH-ЯМР (СОС1з, 300 МГц, д ): 2Н. t, 3,17м.д. ( Гц);1 H NMR (COC1CH, 300 MHz, d): 2H. t, 3.17 ppm. (Hz);

2Н, в5, 4,6 м.д.; 2Н, t, 4,69 м.д. О - 8 Гц); IH, t,2H, b5, 4.6 ppm; 2H, t, 4.69 ppm. O - 8 Hz); IH, t,

7,28 м.д. 0 8 Гц); IH, t, 7,53 м.д. fl 8 Гц); IH, d.7.28 ppm 0 8 Hz); IH, t, 7.53 ppm. fl 8 Hz); IH, d.

57,62 м.д. (| 8 Гц); Ж, d. 7,77 м.д. 0 8 Гц).57.62 ppm (| 8 Hz); F, d. 7.77 ppm 0 8 Hz).

П р и м е р 32. 6Н-(1)Бензопирано(4,3- в)хинолин-7-аминPRI me R 32. 6H- (1) Benzopyrano (4.3-c) quinolin-7-amine

0 По способу, описанному в примере 7, но с применением 4-хроманона вместо дельтавалеролактона получают целевой продукт. 3%, т.пл. 275°С (разлагаетс ).0 By the method described in example 7, but using 4-chromanone instead of deltavalerolactone, the desired product is obtained. 3% mp 275 ° C (decomposes).

IH-ЯМР (ДМСО, 300 МГц, д ): 2Н, S, 5 5,3м.д.; IH, d. 6,97 м.д.1 H NMR (DMSO, 300 MHz, d): 2H, S, 5 5.3 ppm; IH, d. 6.97 ppm

О 8,2 Гц); IH, t, 7-08 м.д. О 7,0 Гц); 2Н, т,O 8.2 Hz); IH, t, 7-08 ppm O 7.0 Hz); 2H, t,

7,15-7,4 м.д.; IH. t, 7,57 м.д. О 7,0 Гц); IH, d, 7,78 м.д.7.15-7.4 ppm; Ih. t, 7.57 ppm O 7.0 Hz); IH, d, 7.78 ppm.

0 (J 7,0 Гц); Ж, d, 8,16 м.д. (f 8,0 Гц); Ж, dd,0 (J 7.0 Hz); W, d, 8.16 ppm. (f 8.0 Hz); F, dd,

8,24 м.д. 0 7,0, 2,0 Гц). П р и м е р 33. 6Н-(1)Бензотиопира- но(4,3-в)хинолин-7-амин.8.24 ppm 0 7.0, 2.0 Hz). PRI me R 33. 6H- (1) Benzothiopyrano (4,3-c) quinolin-7-amine.

5 По способу, описанному в примере 7, но с применением тиохроман-4-она вместо дельта-валеролактона получают целевой продукт, 13%, т.пл. 21Ь2126С.5 By the method described in example 7, but using thiochroman-4-one instead of delta-valerolactone, the target product is obtained, 13%, mp 21b2126c.

Пример 34. 9-Метиламино-8-фтор-4- 0 окса-1,2,3,4-тетрагидроакридинExample 34. 9-Methylamino-8-fluoro-4-0 oxa-1,2,3,4-tetrahydroacridine

По способу, описанному в примере 20, но с применением иодметана вместо циклогексилметилбромида получают целевой продукт (дл  гидрохлорида т.пл. 240°С). 5 IH-ЯМР (ДМСО, 300 МГц, д ): 2Н, т, 2,Ом.д.;2Н, t, 2.95 м.д.By the method described in Example 20, but using iodomethane instead of cyclohexylmethyl bromide, the desired product is obtained (for hydrochloride, mp 240 ° C). 5 IH-NMR (DMSO, 300 MHz, d): 2H, t, 2, Ohm d; 2H, t, 2.95 ppm.

О 6,5 Гц); ЗН, Bd. 3,3 м.д.; 2Н, t. 4,53 м.д. 0 6.5Нц);About 6.5 Hz); ZN, Bd. 3.3 ppm; 2H, t. 4.53 ppm 0 6.5Hz);

IH, dd, 7,34 м.д. 0 8,14 Гц); IH, dd, 7,44 0 м.д.IH, dd, 7.34 ppm. 0 8.14 Hz); IH, dd, 7.44 ppm.

О 8,0 Гц); Ж, т, 7,7-7,8 м.д.; IH, вт, 7,94-8,06 м.д.O 8.0 Hz); W, t, 7.7-7.8 ppm; IH, Tue, 7.94-8.06 ppm.

П р и м е р 35. 2,3-Дигидро-8-фтортие- но(3,2-в)хинолин-9-амин (соединение А) и 5 1,3-Дигидро-8-фтортиено(3,)хинолин-9- аминPRI me R 35. 2,3-Dihydro-8-fluorotheno (3,2-b) quinolin-9-amine (compound A) and 5 1,3-dihydro-8-fluorothieno (3,) quinoline-9-amine

По способу, описанному в примере 12, но с применением 2-амино-6-фторбензо- 0 нитрила вместо антрацилонитрила получают смесь 1:1 обоих целевых продуктов. Соединение А, т.по. 137°С, соединение В (т. пл. 198°С, разлагаетс ):By the method described in Example 12, but using 2-amino-6-fluorobenzo-0 nitrile instead of anthracilonitrile, a 1: 1 mixture of both target products is obtained. Compound A, e.g. 137 ° C, compound B (mp. 198 ° C, decomposes):

IH-ЯМР (CDCfs. 300 МГц, д ):2Н, S, 5 4,09 м.д., 2Н. S,1 H NMR (CDCfs. 300 MHz, d): 2H, S, 5 4.09 ppm, 2H. S

4,38 м.д.; 2Н. в5,5,3 м.д.; Ж, dd, 7,0 м.д.4.38 ppm; 2H. 5.5.5 ppm; W, dd, 7.0 ppm

О 7.3, 14,5 Гц); IH, dd, 7,47 м.д, 0 7,3, 10,5Гц);O 7.3, 14.5 Hz); IH, dd, 7.47 ppm, 7.3, 10.5 Hz);

Ж, d, 7.68 м.д. О-10,5 Гц).F, d, 7.68 ppm O-10.5 Hz).

П р и м о р 36.P r m about r 36.

9-Амино-1,2-дигидроакридин-4(ЗН}-он9-amino-1,2-dihydroacridin-4 (3H} -one

По способу, описанному в примере 1, но с применением 1,2-циклогександиона вместо норкамфоры получают целевой продукт 11 %, т. пл. 240°С (разлагаетс ).By the method described in example 1, but using 1,2-cyclohexanedione instead of norkormora, the target product is 11%, so pl. 240 ° C (decomposes).

1Н-ЯМР(СОС1з.ЗООМГц,3 ):2H,guln, 2.31 м.д.;1 H-NMR (COSl.s. ZOOMHz, 3): 2H, guln, 2.31 ppm;

4Н, mt, 2,8-2,95 м.д.; 2Н , в5, 4,95 м.д.; IH.t, 7,29 м.д.4H, mt. 2.8-2.95 ppm; 2H, b5, 4.95 ppm; IH.t, 7.29 ppm.

О - 8,5 Гц)Ш; t, 7,64 м.д. О - 8,5 Гц); IH, d, 7,74 м.д. .O - 8.5 Hz) W; t, 7.64 ppm O - 8.5 Hz); IH, d, 7.74 ppm. .

О - 8,5 Гц); IH, d, 8,2 м.д. О - 8,51 Гц).O - 8.5 Hz); IH, d, 8.2 ppm. O - 8.51 Hz).

П р и м е р 37. 8-Фтор-9-амино-1,2,3,4- тетрагидроакридинPRI me R 37. 8-Fluoro-9-amino-1,2,3,4-tetrahydroacridine

К перемешиваемому при температуреTo mix at temperature

-20°С раствору циклогексанона (1,0, 10,0-20 ° C solution of cyclohexanone (1.0, 10.0

-ммоль) в метиленхлориде (10 мл) добавл ют 1 М раствор хлорида титана (IV) в метиленхлориде (20 мл). Реакционна  смесь приобретает желтую окраску, и к ней добавл ют смесь триэтиламина (2,0 г, 20 ммоль) и 2- амино-б.-фторбензонитрила .(1i36 г, 10,0 ммоль) в метиленхлориде (30 мл). Реакционна  смесь сразу же становитс  темного цве- та, и ее оставл ют нагреватьс  до комнатной температуры (приблизительно 25°С) и перемешивают еще в течение 15 часов. К концу этого периода реакционную смесь обрабатывают 12% водным раствором гидроксида натри  (100 мл) и метиленх- лоридом(100 мл). Затем реакционную смесь фильтруют через прокладку из диатомовой земли толщиной 2 дюйма (торговое название целит) и прокладку промывают метилен- хлоридом (50 мл) и водой (100 мл). Органический слой отдел ют, промывают водой (1 х 30 мл) и сушат (безводный сульфат магни ). Метиленхлорид удал ют в вакууме и получают целевой продукт в виде белого твердого вещества, 218мг, 10%,т.пл. 175°С.mmol) in methylene chloride (10 ml), a 1 M solution of titanium (IV) chloride in methylene chloride (20 ml) was added. The reaction mixture turns yellow and a mixture of triethylamine (2.0 g, 20 mmol) and 2-amino-b-fluorobenzonitrile (1i36 g, 10.0 mmol) in methylene chloride (30 ml) is added. The reaction mixture immediately turned dark and allowed to warm to room temperature (approximately 25 ° C) and was stirred for another 15 hours. At the end of this period, the reaction mixture was treated with a 12% aqueous solution of sodium hydroxide (100 ml) and methylene chloride (100 ml). The reaction mixture is then filtered through a 2 inch thick pad of diatomaceous earth (trade name Celite) and the pad is washed with methylene chloride (50 ml) and water (100 ml). The organic layer was separated, washed with water (1 x 30 ml) and dried (anhydrous magnesium sulfate). The methylene chloride was removed in vacuo to give the desired product as a white solid, 218 mg, 10%, mp. 175 ° C.

П р и м е р 38. 9-Амино-8-метил-1,2,3,4- тетрагидроакридинPRI me R 38. 9-amino-8-methyl-1,2,3,4-tetrahydroacridine

По способу, описанному в примере 37, но с применением 2-амино-6-метилбензо- нитрила вместо 2-амино-6-фторбензонитри- ла получают целевой продукт, 11%, т.пл. 143-145°С.By the method described in example 37, but using 2-amino-6-methylbenzonitrile instead of 2-amino-6-fluorobenzonitrile, the desired product is obtained, 11%, mp. 143-145 ° C.

П р и м е р 39. 9-Амино-8-хлор-1,2,3,4- тетрагидроакридинPRI me R 39. 9-amino-8-chloro-1,2,3,4-tetrahydroacridine

По способу, описанному в примере 37, но с применением 2-амино-6-хлорбензонит- рила вместо 2-амино-6-фторбензонитрила получают целевой продукт, 23%, т.пл. 144- 145°С.By the method described in example 37, but using 2-amino-6-chlorobenzonitrile instead of 2-amino-6-fluorobenzonitrile, the desired product is obtained, 23%, mp. 144-145 ° C.

П р и м е р 40. 4-Амино-5-фтор-2,3-пен- таметиленхинолинPRI me R 40. 4-amino-5-fluoro-2,3-pentamethylene quinoline

По способу, описанному в примере 37, но с применением циклогептанона вместоBy the method described in example 37, but using cycloheptanone instead

циклогексанона получают целевой продукт, 22%, т.пл. 203°С.cyclohexanone receive the target product, 22%, so pl. 203 ° C.

П р и м е р 41. 4-Амино-5-хлор-2,3-пен- таметиленхинолинPRI me R 41. 4-amino-5-chloro-2,3-pentamethylene quinoline

По способу, описанному в примере 37, но с применением циклогептанона вместо циклогексанона и 2-амино-6-хлорбензонит- рила вместо 2-амино-6-фторбензонитрила получают целевой продукт, 11%, т.пл. 194- 195°С.By the method described in example 37, but using cycloheptanone instead of cyclohexanone and 2-amino-6-chlorobenzonitrile instead of 2-amino-6-fluorobenzonitrile, the desired product is obtained, 11%, mp. 194 - 195 ° C.

Пример 42. 4-Амино-5-фтор-2,3-три- метиленхинолинExample 42. 4-amino-5-fluoro-2,3-trimethylenequinoline

По способу, описанному в примере 37, но с применением циклопентанона вместо циклогексанона получают целевой продукт, 6% т.пл. 179-18ГС.By the method described in example 37, but using cyclopentanone instead of cyclohexanone, the desired product is obtained, 6% mp 179-18GS.

П р и м е р 43. 9-Амино-8-хлор-4-оксо- 1,2,3,4-тетрагидроакридинPRI me R 43. 9-amino-8-chloro-4-oxo-1,2,3,4-tetrahydroacridine

По способу, описанному в примере 7, но с применением 2-амино-6-хлорбензонитри- ла вместо антранилонитрила получают целевой продукт, 1,5%, т.пл. 205°С.By the method described in example 7, but using 2-amino-6-chlorobenzonitrile instead of anthranilonitrile, the desired product is obtained, 1.5%, mp. 205 ° C.

Пример 44. 9-Амино-8-метил-4-окса- ,1,2,3,4-тетрагидроакридин По способу, описанному в примере 7, но с применением 2-амино-6-метилбензонит- рила вместо антранилонитрила получают целевой продукт, 20%, т.пл. 177-179°С.Example 44. 9-amino-8-methyl-4-oxa-, 1,2,3,4-tetrahydroacridine By the method described in example 7, but using 2-amino-6-methylbenzonitrile instead of anthranilonitrile, the desired product is obtained , 20%, mp 177-179 ° C.

1Н-ЯМР (CDCI3, 300 МГц, д ); IH, d, 7,56 м.д. 0 7 Гц);1 H NMR (CDCI 3, 300 MHz, d); IH, d, 7.56 ppm. 0 7 Hz);

IH, t, 6,95 м.д. 0 7 Гц); 2Н, в5,4,93 м.д.; 2H,t,IH, t, 6.95 ppm. 0 7 Hz); 2H, b, 5.4.93 ppm; 2H, t,

4,29 м,д. 0 6 Гц); ЗН, S, 2,89 м.д.; 2Н, t, 2,52 м.д. 0 6Гц);2Н, т, 2,08-2,11 м.д.4.29 m, d. 0 6 Hz); ZN, S, 2.89 ppm; 2H, t, 2.52 ppm. 0 6Hz); 2H, t, 2.08-2.11 ppm.

Пример 45. 9-Амино-8-метокси- 1,2,3,4-тетрагидроакридинExample 45. 9-amino-8-methoxy-1,2,3,4-tetrahydroacridine

По способу, описанному в примере 37,By the method described in example 37,

но с применением 2-амино-6-метоксибензонитрила вместо 2-амино-6-фторбензонитрила получают целевой продукт, 14%, т.пл.but using 2-amino-6-methoxybenzonitrile instead of 2-amino-6-fluorobenzonitrile, the desired product is obtained, 14%, mp.

187-188°С.187-188 ° C.

П р и м е р 46. 9-Амино-8-метокси-4-ок- са-1,2,3,4-тетрагидроакридин По способу, описанному в примере 7, но с применением 2-амино-6-метоксибензо- нитрила вместо антранилонитрила получают целевой продукт, 11%, т.пл. 205 207°С. Ш-ЯМР (CDCIs, 300 МГц, д ): 2Н, т, 7.33 м.д.; IH, dd,PRI me R 46. 9-amino-8-methoxy-4-oxa-1,2,3,4-tetrahydroacridine According to the method described in example 7, but using 2-amino-6-methoxybenzo- nitrile instead of anthranilonitrile get the target product, 11%, so pl. 205 207 ° C. W-NMR (CDCIs, 300 MHz, d): 2H, t, 7.33 ppm; IH, dd,

6,57 м.д. 0 3,6 Гц); 2Н BS, 5,92 м.д.; 2Н, t, 4,29 м.д.6.57 ppm 0 3.6 Hz); 2H BS, 5.92 ppm; 2H, t, 4.29 ppm.

О 2,6 Гц); ЗН, S, 3,95 м.д.; 2Н. t, 2,5 м.д. О 2,6 Гц) 2Н, т. 2,13-2,07 м.д.About 2.6 Hz); ZN, S, 3.95 ppm; 2H. t, 2.5 ppm O 2.6 Hz) 2H, t, 2.13-2.07 ppm.

Пример 47. Способность соединений 1-16, 18, 26-29 и 35-46, подавл ть ацетил- холинстеразу мозга была определена спек- трофотометрическим методом. Дл  всехExample 47. The ability of compounds 1-16, 18, 26-29 and 35-46 to suppress brain acetylcholinesterase was determined spectrophotometrically. For all

188±16188 ± 16

500 ±187500 ± 187

600 ±163600 ± 163

230 ± 18230 ± 18

345 ± 18345 ± 18

272 ± 78272 ± 78

482 ± 147482 ± 147

318 ±64318 ± 64

395 ±118395 ± 118

308± 73308 ± 73

815 ±335815 ± 335

700700

SU884356604A 1987-10-05 1988-10-04 Process for preparing 4-aminopyridine derivatives RU1816283C (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1987/002546 WO1989002739A1 (en) 1987-10-05 1987-10-05 4-aminopyridine derivatives

Publications (1)

Publication Number Publication Date
RU1816283C true RU1816283C (en) 1993-05-15

Family

ID=22202587

Family Applications (1)

Application Number Title Priority Date Filing Date
SU884356604A RU1816283C (en) 1987-10-05 1988-10-04 Process for preparing 4-aminopyridine derivatives

Country Status (12)

Country Link
KR (1) KR900007243B1 (en)
AT (1) ATE123024T1 (en)
DD (1) DD273633A5 (en)
EG (1) EG19973A (en)
FI (1) FI93117C (en)
MX (1) MX13270A (en)
MY (1) MY104335A (en)
PL (1) PL159258B1 (en)
PT (1) PT88656B (en)
RU (1) RU1816283C (en)
WO (2) WO1989002739A1 (en)
ZA (1) ZA887399B (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4897400A (en) * 1987-02-13 1990-01-30 Hoeschst-Roussel Pharmaceuticals, Inc. 9-amino-1,4-ethano-1,2,3,4-tetrahydroacridine and related compounds useful for incresing the cholinergic function in a mammal
US5002955A (en) * 1987-04-23 1991-03-26 Hoechst-Roussel Pharmaceuticals Inc. Fused heteroalkylene quinolinamines and use as cholinergic agents
US5013741A (en) * 1987-09-08 1991-05-07 Hoechst-Roussel Pharmaceuticals Incorporated N-[substituted alkylidene]-1,2,3,4-tetrahydro-9-acridinamines useful for enhancing the cholinergic function in a mammal
US5037833A (en) * 1988-07-25 1991-08-06 Hoechst-Roussel Pharmaceuticals Inc. N-[substituted alkylidene]fused-bicycloalkylidene quinolinamines useful for enhancing the cholinergic function in a mammal
US4927820A (en) * 1988-11-25 1990-05-22 Hoechst Roussel Pharmaceuticals Inc. Fused heterocyclic derivatives of 1,2,3,4-tetrahydroacridine
CA2029497C (en) * 1989-11-08 2002-06-04 Kunihiro Ninomiya (Deceased) 4-acylaminopyridine derivative
US5112829A (en) * 1989-11-28 1992-05-12 Hoechst-Roussel Pharmaceuticals Inc. Hexahydro-1H-quino[4,3,2-ef][1,4]benzoxazepines and related compounds
US4994452A (en) * 1989-11-28 1991-02-19 Hoechst-Roussel Pharmaceuticals Inc. Hexahydro-1H-quino[4,3,2-ef][1,4]benzoxazepines and related compounds
US5210087A (en) * 1991-02-13 1993-05-11 Hoechst-Roussel Pharmaceuticals Inc. 9-aminotetrahydroacridines and related compounds
US5234947A (en) * 1991-11-07 1993-08-10 New York University Potassium channel activating compounds and methods of use thereof
US5422350A (en) * 1992-09-10 1995-06-06 Warner-Lambert Company Nitrogen substituted acridine and cytochrome P450 inhibitors and methods of use
US5466696A (en) * 1992-09-10 1995-11-14 Warner Lambert Company Tacrine and cytochrome P450 oxidase inhibitors and methods of use
US5783584A (en) * 1995-12-11 1998-07-21 Mayo Foundation For Medical Education And Research THA analogs useful as cholinesterase inhibitors
US5929093A (en) * 1996-06-13 1999-07-27 Mayo Foundation For Medical Education And Research Bifunctional acetylcholinesterase reactivators
DE19707655A1 (en) * 1997-02-26 1998-08-27 Hoechst Ag Combination preparation for use in dementia
DE10111728A1 (en) * 2001-03-09 2002-09-12 Merck Patent Gmbh UV filter
CA2578164A1 (en) 2004-09-07 2006-03-16 Wyeth 6h-[1]benzopyrano[4,3-b]quinolines and their use as estrogenic agents
CN114853672B (en) * 2022-05-12 2023-06-23 中国人民解放军北部战区总医院 Tacrine derivatives as CDKs inhibitors and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3232945A (en) * 1962-08-13 1966-02-01 S E Massengill Company 7,8,9,10-tetrahalo-6h-cyclohepta-(b)-quinolines
US3318896A (en) * 1963-12-05 1967-05-09 Squibb & Sons Inc Production of 12-substituted-6, 7, 8, 9, 10, 11-hexahydrocycloocta[b]quinolines
GB1186062A (en) * 1966-03-14 1970-04-02 American Home Prod Benzonaphthyridine Derivatives
US3541066A (en) * 1968-09-16 1970-11-17 American Home Prod 2,3-dihydro-1,4-ethanobenzo(b)(1,5)naphthyridine derivatives
US4180580A (en) * 1976-11-08 1979-12-25 American Home Products Corp. Furo(3,4-b)quinolines
US4550113A (en) * 1982-08-19 1985-10-29 Nauchno-Issledovatelsky Institut Po Biologicheskikm Ispytaniyam Khimicheskikh Soedineny 9-Amino-2,3,5,6,7,8-hexahydro-1H-cyclopenta(b)quinoline monohydrate hydrochloride as stimulant of neuro-muscular transmission of smooth muscles
US4680298A (en) * 1983-05-31 1987-07-14 Schering Corporation Tricyclic anti-allergy and use as anti-inflammatory agents
US4680297A (en) * 1983-07-14 1987-07-14 Schering Corporation Tricyclic positive inotropic agents
US4631286A (en) * 1984-10-25 1986-12-23 Hoechst-Roussel Pharmaceuticals Inc. 9-amino-1,2,3,4-tetrahydroacridin-1-ol and related compounds
US4695573A (en) * 1984-10-25 1987-09-22 Hoechst-Roussel Pharmaceuticals Inc. 9-amino-1,2,3,4-tetrahydroacridin-1-ol and related compounds
US4578394A (en) * 1984-12-10 1986-03-25 Hoechst-Roussel Pharmaceuticals Incorporated Cholinergic function increasing 3-[N-(pyridyl) carbamoyl]-1,4-dihydropyridines
US4652567A (en) * 1985-03-13 1987-03-24 Hoechst-Roussel Pharmaceuticals Inc. Benzo(c)-1,5-naphthyridines useful for treating a patient having drug induced memory impairment in need of memory enhancement

Also Published As

Publication number Publication date
PT88656B (en) 1992-12-31
FI93117B (en) 1994-11-15
FI884553A0 (en) 1988-10-04
PT88656A (en) 1988-11-01
PL159258B1 (en) 1992-12-31
WO1989002740A1 (en) 1989-04-06
EG19973A (en) 1996-10-31
ZA887399B (en) 1990-05-30
DD273633A5 (en) 1989-11-22
WO1989002739A1 (en) 1989-04-06
KR890006590A (en) 1989-06-14
FI93117C (en) 1995-02-27
MY104335A (en) 1994-03-31
PL275056A1 (en) 1989-05-30
KR900007243B1 (en) 1990-10-06
MX13270A (en) 1993-06-01
ATE123024T1 (en) 1995-06-15
FI884553A (en) 1989-04-06

Similar Documents

Publication Publication Date Title
RU1816283C (en) Process for preparing 4-aminopyridine derivatives
IE62858B1 (en) Substituted flavonoid compounds their salts their manufacture and medicines containing these materials
DE2757503A1 (en) 5.6-DIHYDROBENZO SQUARE CLAMP ON 5.6 SQUARE BRACKET FOR CYCLOHEPTA SQUARE BRACKET ON 1.2-ANGLE BRACKET FOR PYRAZOLO SQUARE BRACKET ON 4.3-SQUARE BRACKET FOR -PYRIDINE-11 (1H) -ONE AND -IMINE AND THEIR SALTS AND THE USE OF THESE COMPOUNDS AS PSYCHOTROPIC AND ANTI-INFLAMMATORY DRUGS
EP0311303A2 (en) 4-aminopyridine derivatives
US5541329A (en) Intermediates prepared in an asymmetric total synthesis of camptothecin analogs
SU719499A3 (en) Method of preparing 1,2,3,4,6,7-hexahydro-11 b alpha-h-benzo(alpha)-quinolysin derivatives or their salts
US4670462A (en) Substituted 1,3,4,9-tetrahydropyrano(3,4-B)indole-1-acetic acids
NO149737B (en) ANALOGY PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE 1-AZAXANTHON-3-CARBOXYLIC ACIDS
Baba et al. Studies on disease-modifying antirheumatic drugs. IV. Synthesis of novel thieno [2, 3-b: 5, 4-c'] dipyridine derivatives and their anti-inflammatory effect
JPH059177A (en) New nitrogen-containing heterocyclic compound
CA2052287A1 (en) Tricyclic heterocyclic compounds, their production and use
HU180917B (en) Process for preparing 5,6,6a,7-tetrahydro-benzo/c/quinolin -9/8h/-one derivatives
Moffett Azacoumarins
EP1064265B8 (en) Synthesis of 3-amino-2-chloro-4-methylpyridine from malononitrile and acetone
EP0238226B1 (en) Substituted 1,3,4,9-tetrahydropyrano [3,4-b]indole-1-acetic acids
US5202440A (en) Certain 9-amino-2-(or 4)-oxa 1,2,3,4-tetrahydro- or 1,2,3,4,5,6,7,8-octahydro-acridines
SU725563A3 (en) Method of preparing imidazo-(1,5-a)(1,4) diazepine derivatives or their salts
US4716167A (en) 2-amino-5-oxo-5H-[1]benzopyrano[2,3-b]pyridine-3-carboxylic acid derivatives
RU2039058C1 (en) 4-aminopyridine derivatives
KR100249637B1 (en) Derivatives of fluoro-quinoline carboxylic-3-acid and preparation therefor
Castle et al. A new method for the synthesis of substituted indeno [1, 2‐b] thiophene with subsequent ring expansion to form substituted thieno [3, 2‐c] quinoline
US4775690A (en) Substituted 1,3,4,9-tetrahydropyrano(3,4-b)indole-1-acetic acids
US4971960A (en) Substituted 1,3,4,9-tetrahydropyrano(3,4-b)indole-1-acetic acids
US4017490A (en) Pyrido (3,4-d)pyridazines
Mataka et al. Preparation of hexa‐, penta‐and tetraphenyl‐2, 6‐and‐2, 7‐naphthyridines